Find Funding Opportunities

Find Funding Opportunities

Subscribe to Find Funding OpportunitiesRSS
Filter By:
Returning 192 results

Notice of Special Interest (NOSI): Common Fund ALS-related Transformative Research Award (R01 Clinical Trial Optional)

Notice of Special Interest
Wednesday, June 17, 2020
Sunday, January 1, 2023
R01
NOT-RM-20-019
Amelie Gubitz

Funding Opportunity Purpose

Notice Special Interest NOSI): Common Fund ALS-related Transformative Research Award R01 Clinical Trial Optional) Notice Number: NOT-RM-20-019 Key Dates Release Date: June 17, 2020 Related Announcements RFA-RM-20-013 - NIH Director’s Transformative Research Awards R01 Clinical Trial Optional) Issued Office Strategic Coordination Common Fund) National Institute Aging NIA) National Institute Environmental Health Sciences NIEHS) National Institute General Medical Sciences NIGMS) National Institute Neurological Disorders Stroke NINDS) Purpose purpose this Notice to inform potential applicants the special interest the Office Strategic Coordination Common Fund), National Institute Neurological Disorders Stroke NINDS), National Institute Aging NIA), National Institute Environmental Health Sciences NIEHS), National Institute General Medical Sciences NIGMS) supporting exceptionally innovative research the basic biology Amyotrophic Lateral Sclerosis through NIH Director’s Transformative Research Award initiative. Background: Amyotrophic lateral sclerosis ALS) a devastating disease no known cure. is neurodegenerative disease causes death motor neurons control voluntary muscles. results weakness ultimately loss voluntary muscle function. ALS rapidly progressive always fatal. people die within 3-5 years developing symptoms. cause ALS unknown likely involves combination genetic environmental risk factors. 5 – 10% cases familial the remaining cases considered be sporadic. Hampered the unknown etiology ALS despite extensive efforts, only drugs been developed are FDA approved these drugs extend life just few months do improve symptoms. Thus, development effective ALS therapeutics benefit tremendously investing basic ALS research tests highly novel concepts, brings together researchers different scientific perspectives, applies powerful emerging technologies a variety disciplines. Though such highly innovative research be inherently risky, potential payoff our understanding ALS warrant risk. solicit support such high-risk, high-reward ALS-related research, Accelerating Leading-edge Science ALS ALS2) being created. ALS2 use existing NIH Director’s Transformative Research Award initiative receive review applications. initiative part the NIH Common Fund’s High-Risk, High-Reward Research HRHR) Program. HRHR program offers time-tested, powerful approach sparking innovation impact. Transformative Research Award initiative a particularly well-suited initiative within HRHR program supporting interdisciplinary teams scientists proposing combine expertise pursue highly innovative ideas. Transformative Research Award applications not require preliminary data a detailed experimental plan. Rather, emphases unusually high magnitude potential impact, exceptional degree innovation, a highly compelling logic the approach. note, anonymized review process the Transformative Research Award applications being piloted year help maintain focus these emphases. Large budgets exceeding 500,000 direct costs any given year) acceptable without pre-approval must commensurate the scope the project. Objective objective this Notice to advance dramatically our understanding the complex biology ALS. Thus, applications use or of following elements encouraged: Adapt emerging tools technologies neuroscience, cell biology other disciplines identify causes ALS how disease progresses, forming basis new potential therapeutic strategies. Attract new talent a range scientific disciplines, including cell biology, bioengineering, chemistry, biophysics, environmental health sciences, computational science, initiate new interdisciplinary collaborations. Explore potential similarities between ALS other neurodegenerative disorders beyond, including, not limited to, frontotemporal dementia, chronic traumatic encephalopathy, Kennedy’s disease, spinal muscular atrophy, primary lateral sclerosis, aging-induced neuromuscular degeneration. Application, Review, Funding Information Applications must submitted response FOA RFA-RM-20-13. instructions the FOA must followed. addition, applications must indicate “NOT-RM-20-019” without quotation marks) the Agency Routing Identifier field Box 4b) the SF424 R&R) Form. Applications without information Box 4b not considered support the ALS2 program. receipt date September 30, 2020. Applications be reviewed using same review process for other Transformative Research Award applications described RFA-RM-20-013. Funding applications submitted through Notice be considered separately other TRA applications will based the results peer review programmatic priorities. Inquiries Please direct inquiries to: Amelie K. Gubitz, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-5680 Email:gubitza@ninds.nih.gov Ravi Basavappa Office the Director OD) Telephone: 301-435-7204 Email:Transformative_Awards@mail.nih.gov Lisa Opanashuk, Ph.D. National Institute Aging NIA) Telephone: 301-82705422 Email: lisa.opanashuk@nih.gov Jonathan A. Hollander, Ph.D. National Institute Environmental Health Sciences NIEHS) Telephone: 984-287-3269 Email: jonathan.hollander@nih.gov Oleg Barski, Ph.D. National Institute General Medical Sciences NIGMS) Telephone: 301-496-1511 Email: oleg.barski@nih.gov

Notice of Special Interest (NOSI): Chimerism in Marmosets and other New World Primates

Notice of Special Interest
Wednesday, June 3, 2020
Saturday, January 8, 2022
NOT-MH-20-048
James Gnadt

Funding Opportunity Purpose

Notice Special Interest NOSI): Chimerism Marmosets other New World Primates Notice Number: NOT-MH-20-048 Key Dates Release Date: June 3, 2020 First Available Due Date: October 05, 2020 Expiration Date: January 08, 2022 Related Announcements PA-20-185 - NIH Research Project Grant Parent R01, Clinical Trial Allowed) PA-20-195 - NIH Exploratory/Developmental Research Grant Program Parent R21, Clinical Trial Allowed) Issued National Institute Mental Health NIMH) National Institute Aging NIA) National Institute Allergy Infectious Diseases NIAID) National Institute Drug Abuse NIDA) National Institute Neurological Disorders Stroke NINDS) Purpose purpose this Notice to inform potential applicants the National Institutes Health NIH) a special interest research project applications focusing understanding biological basis functional implications chimerism the common marmoset Callithrix jacchus) other callitrichid primates. interest applications focus the following areas: 1) stem cell exchange utero, extent molecular mechanisms associated the induction maintenance hematopoietic chimerism, the possibility somatic and/or germ line chimerism the adult animal; 2) development systems assays study cellular heterogeneity resulting chimerism potential intragenomic conflict within individual’s tissues; and, 3) understanding molecular cellular impact chimerism biological processes, including development, metabolism, cognition, social behavior, aging, immunological suppression reactivity, reproduction; well effects and mechanisms associated transplant tolerance. Background Nonhuman primates NHP) the closest evolutionary relatives humans, whom share anatomical, physiological, gene interaction features. common marmoset Callithrix jacchus) of increasing importance biomedical research worldwide, aided its small body size, shorter life span compared macaques, rapid reproductive maturation, making ideal genetic transgenerational research. New World primate also known cooperative social behavior, cognition, communication, potentially makes a good model organism contribute our understanding a wide range human biology diseases, are currently being extensively used study family interactions, hormonal development, reproduction, infectious diseases, neurodegenerative disorders age-related hearing loss. Marmosets obligate litter bearers most pregnancies resulting dizygotic twins show chimerism the blood other cells the hematopoietic lineage, a result in utero exchange stem cells through placental anastomoses during early development, process leads lifelong chimerism. Chimerism previously reported most marmoset tissues including skin, hair, brain, lung, blood, lymphatic tissues, muscle. However, recent quantitative studies indicate chimerism limited cells the hematopoietic lineage, that previous observation widespread tissue chimerism likely due blood lymphocyte infiltration those tissues, fibroblast cell lines chimeric individuals not chimeric. evolutionary functional consequences hematopoietic chimerism, is unique marmosets other callitrichid primates, currently unknown. is also known chimerism limits enhances use these animals models human physiology, health disorders. example, studies focused immune response the marmoset should cognizant the potential confounding effect chimeric lymphocytes. Therefore, this model reach full translational utility furthering our understanding human health diseases, is imperative we achieve better understanding the functional consequences chimerism its contributions health, behavior diseases New World primates. Research Objectives Applications response this NOSI should aligned the overall purpose, is improve our understanding the biological physiological significance chimerism this NHP model. Research areas include are limited to: stem cell exchange utero, extent molecular mechanisms/pathways associated the induction maintenance hematopoietic chimerism, mechanisms associated maintenance loss chimerism the bone marrow, blood, thymus, lymphoid tissues juveniles adults; the possibility somatic germ line chimerism the adult animal; development systems assays study cellular heterogeneity resulting chimerism; comparisons major histocompatibility complex genes proteins expressed dizygotic twin pairs; potential intragenomic conflict within individual’s tissues; understanding molecular cellular impact chimerism biological processes, including development, metabolism, cognition, social behavior, aging, immunological suppression reactivity, reproduction; medical interventions including organ cellular transplantation focus evaluation the immune response elicited a sibling twin third party donor organ e.g., kidney, heart, lung) cellular e.g., bone marrow islet) transplant mechanisms associated transplant tolerance rejection. Application Submission Information notice applies due dates or after October 5, 2020 subsequent receipt dates through January 8, 2022. Submit applications this initiative using of following funding opportunity announcements FOAs) any reissues these announcement through expiration date this notice PA-20-185: NIH Research Project Grant Parent R01 Clinical Trial Allowed) PA-20-195: NIH Exploratory/Developmental Research Grant Program Parent R21, Clinical Trial Allowed) instructions the SF424 R&R) Application Guide the funding opportunity announcement used submission must followed, the following additions: funding consideration, applicants must include “NOT-MH-20-048” without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Although NIMH NINDS not listed a Participating Organization all FOAs listed above, applications this initiative be accepted. Applications nonresponsive terms this NOSI be withdrawn consideration this initiative. Inquiries Please direct inquiries the contacts Section VII the listed funding opportunity announcements the following additions/substitutions: Scientific/Research Contact(s) Abigail Soyombo, Ph.D., MBA National Institute Mental Health NIMH) Telephone: 301-827-7329 Email: abigail.soyombo@nih.gov Manuel Moro, DVM, Ph.D. National Institute Aging NIA) Telephone: 301-480-1796 Email: manuel.moro@nih.gov Julia Shaw, Ph.D. National Institute Allergy Infectious Diseases NIAID) Telephone: 240-627-3711 Email: julia.shaw@nih.gov Amy C. Lossie, PhD National Institute Drug Abuse NIDA) Telephone: 301) 827-6092 Email:amy.lossie@nih.gov James Gnadt, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-9964 Email:gnadtjw@ninds.nih.gov Peer Review Contact(s) Examine eRA Commons account review assignment contact information information appears weeks after submission due date). Financial/Grants Management Contact(s) Theresa Jarosik National Institute Mental Health NIMH) Telephone: 301-443-3858 Email: tjarosik@mail.nih.gov

Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)

PA
Friday, May 29, 2020
Workforce Diversity
Monday, May 8, 2023
PA-20-222

Funding Opportunity Purpose

The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention hereby notify Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) holding specific types of research grants (activity codes listed above) that funds are available for administrative supplements to enhance the diversity of the research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from diverse backgrounds, including those from groups that have been shown to be underrepresented in health-related research. This supplement opportunity is also available to PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project. Administrative supplements must support work within the scope of the original project. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

Eradication of HIV-1 from Central Nervous system Reservoirs (R01 Clinical Trial Not Allowed)

PA
Wednesday, May 13, 2020
Monday, May 8, 2023
R01
PA-20-151
May Wong

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) invites research grant applications studying mechanisms of HIV-1 persistence and eradication strategies specifically focused on the central nervous system (CNS) in the context of viral suppression. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required

HIV Infection of the Central Nervous System (R01 Clinical Trial Not Allowed)

PA
Wednesday, May 13, 2020
Monday, May 8, 2023
R01
PA-20-149
May Wong

Funding Opportunity Purpose

The goals of this Funding Opportunity Announcement (FOA) are to stimulate further research on delineating the pathophysiology of HIV-1 associated CNS disease in the setting of chronic viral suppression and ART. In addition, FOA also encourages research studies to aid in the identification/ validation of biomarkers and pre-clinical targets with quantifiable readouts in domestic and international settings. Multidisciplinary research teams and collaborative alliances are encouraged but not required.

Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed)

PA
Tuesday, May 12, 2020
Monday, May 8, 2023
K08
PA-20-203

Funding Opportunity Purpose

The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research.

Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required)

PA
Tuesday, May 12, 2020
Monday, May 8, 2023
K08
PA-20-202

Funding Opportunity Purpose

The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research.

Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Basic Experimental Studies with Humans Required)

PA
Tuesday, May 12, 2020
Monday, May 8, 2023
K08
PA-20-201

Funding Opportunity Purpose

The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research.

Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required)

PA
Tuesday, May 12, 2020
Monday, May 8, 2023
K23
PA-20-206

Funding Opportunity Purpose

The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research.

Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed)

PA
Monday, May 11, 2020
Monday, May 8, 2023
K23
PA-20-205

Funding Opportunity Purpose

The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research.

Pages